ATA3219

About Atara Biotherapeutics

Atara Biotherapeutics is focused on unleashing the power of the body's immune system by developing next-generation, allogeneic T-cell immunotherapies. Its core technology utilizes donor-derived EBV T cells, which do not require T-cell receptor or HLA gene editing, enabling the creation of scalable, off-the-shelf treatments. The company has achieved the landmark approval of EBVALLO™ for post-transplant lymphoproliferative disease and is advancing a pipeline of next-generation CAR T candidates for B-cell cancers and autoimmune diseases. Atara's strategy centers on overcoming the limitations of current autologous cell therapies through rapid delivery and scalable manufacturing.

About Atara Biotherapeutics

Atara Biotherapeutics is focused on unleashing the power of the body's immune system by developing next-generation, allogeneic T-cell immunotherapies. Its core technology utilizes donor-derived EBV T cells, which do not require T-cell receptor or HLA gene editing, enabling the creation of scalable, off-the-shelf treatments. The company has achieved the landmark approval of EBVALLO™ for post-transplant lymphoproliferative disease and is advancing a pipeline of next-generation CAR T candidates for B-cell cancers and autoimmune diseases. Atara's strategy centers on overcoming the limitations of current autologous cell therapies through rapid delivery and scalable manufacturing.

Therapeutic Areas